Sydney, Australia (BUSINESS WIRE) - Frost & Sullivan has appointed Mr Maz Khan as Director for its Pharmaceutical team in Australia.
With current big pharma strategy seeming to be more focused in chosen core areas of specialization like specialty pharmaceuticals and biotech, rather than the traditional blockbuster approach, Australia has a strong position as a significant research base. "Despite having only 0.3 per cent of the world's population and a pharmaceutical market that is approximately 1.0 per cent of the global market, Australia contributes 2.5 per cent towards the world's medical research and 2.9 per cent to global scientific publications," says Jonathan Raja, Director of Australia Healthcare Practice, Frost & Sullivan.
Mr Raja added that "Australia is clearly one of the world's preferred location to conduct global clinical trials, and as at quarter four 2007, there were 50 Phase I trials, 153 Phase 2 trials, 262 Phase 3 and 65 Phase 4 trials being conducted here.
However, with the increasing patient base that needs treatment due to increased prevalence and advances in diagnostics, the challenges of costs have driven pharmacoeconomics to emerge as one of the vital research areas. Communicating the cost-benefit of products is an important contributor to commercial success and Frost & Sullivan foresees further increase in use of pharmacoeconomic analyses, such as price threshold and market uptake from the access population, as part of a comprehensive to-market strategy.""Maz Khan is a strong addition to the Australia Healthcare team," he said.
In his new role at Frost & Sullivan, Mr Khan will be responsible in expanding the team and working closely with the clients in the country and region. As a Market research executive with extensive pharmaceutical experience in managing business intelligence and sales and marketing effectiveness functions, he will be working to increase the visibility of the pharmaceutical team, and identifying more effective ways to partner with companies to generate and evaluate market data and implement their strategic plans, at both the brand and corporate levels.
"I am making an exciting move in my career, where I will be capitalizing on all my previous experiences to further add to Frost & Sullivan's standing in Australia and to provide top value added services to its pharmaceutical clients," Mr Khan said.
Mr Khan brings with him a rich 20 years of experience in the Australian healthcare industry. Mr Khan has previously lead Market Research and Business Intelligence functions in multinational companies such as Eli Lilly, Aventis and Wyeth.
Mr Raja also said that it is an important move for our healthcare business to include someone like Maz Khan. "He brings to our team a wealth of local knowledge and exceptional skills which will strengthen our partnerships and add clear value to the work we do in the Pharmaceutical industry," he added.
"Frost & Sullivan's pharmaceutical & biotechnology group works with leading multinational companies in Australia and has formed a global team of experts to support our partners in the expansion of their businesses. We have a strong commitment to increasing our expertise in the pharmaceutical and biotechnology space globally, and having Maz Khan on the team will further strengthen our local and global pharmaceutical expertise and operations," says Ms. Rhenu Bhuller, Global Vice President, Pharmaceuticals/ Biotechnology Practice, Frost & Sullivan.
Frost & Sullivan Healthcare Practice has a team of more than 90 experienced analysts in Asia Pacific dedicated to research in the pharmaceuticals, medical devices, biotechnology, healthcare IT markets as well as emerging technology trends in the region.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, partners with clients to accelerate their growth. The company's TEAM Research, Growth Consulting and Growth Team Membership empower clients to create a growth-focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents. For more information about Frost & Sullivan's Growth Partnerships, visit http://www.frost.com.
Frost & Sullivan Corporate Communications Healthcare,
Asia Pacific Jasminder KaurDid: +65 6890 0937 Mobile: +65 9062 7051
jkaur@frost.com or Corporate Communications Healthcare,
Asia Pacific Shereen GillDid: +603 6204 5909 Mobile: +6017 617 8300
shereen.gill@frost.com or Australia officeSuite 1, Level 9189
Kent StreetSydney, NSW AustraliaTel: +61 (0)2 8247 9800 Fax:
+61 (0)2 9252 8066
With current big pharma strategy seeming to be more focused in chosen core areas of specialization like specialty pharmaceuticals and biotech, rather than the traditional blockbuster approach, Australia has a strong position as a significant research base. "Despite having only 0.3 per cent of the world's population and a pharmaceutical market that is approximately 1.0 per cent of the global market, Australia contributes 2.5 per cent towards the world's medical research and 2.9 per cent to global scientific publications," says Jonathan Raja, Director of Australia Healthcare Practice, Frost & Sullivan.
Mr Raja added that "Australia is clearly one of the world's preferred location to conduct global clinical trials, and as at quarter four 2007, there were 50 Phase I trials, 153 Phase 2 trials, 262 Phase 3 and 65 Phase 4 trials being conducted here.
However, with the increasing patient base that needs treatment due to increased prevalence and advances in diagnostics, the challenges of costs have driven pharmacoeconomics to emerge as one of the vital research areas. Communicating the cost-benefit of products is an important contributor to commercial success and Frost & Sullivan foresees further increase in use of pharmacoeconomic analyses, such as price threshold and market uptake from the access population, as part of a comprehensive to-market strategy.""Maz Khan is a strong addition to the Australia Healthcare team," he said.
In his new role at Frost & Sullivan, Mr Khan will be responsible in expanding the team and working closely with the clients in the country and region. As a Market research executive with extensive pharmaceutical experience in managing business intelligence and sales and marketing effectiveness functions, he will be working to increase the visibility of the pharmaceutical team, and identifying more effective ways to partner with companies to generate and evaluate market data and implement their strategic plans, at both the brand and corporate levels.
"I am making an exciting move in my career, where I will be capitalizing on all my previous experiences to further add to Frost & Sullivan's standing in Australia and to provide top value added services to its pharmaceutical clients," Mr Khan said.
Mr Khan brings with him a rich 20 years of experience in the Australian healthcare industry. Mr Khan has previously lead Market Research and Business Intelligence functions in multinational companies such as Eli Lilly, Aventis and Wyeth.
Mr Raja also said that it is an important move for our healthcare business to include someone like Maz Khan. "He brings to our team a wealth of local knowledge and exceptional skills which will strengthen our partnerships and add clear value to the work we do in the Pharmaceutical industry," he added.
"Frost & Sullivan's pharmaceutical & biotechnology group works with leading multinational companies in Australia and has formed a global team of experts to support our partners in the expansion of their businesses. We have a strong commitment to increasing our expertise in the pharmaceutical and biotechnology space globally, and having Maz Khan on the team will further strengthen our local and global pharmaceutical expertise and operations," says Ms. Rhenu Bhuller, Global Vice President, Pharmaceuticals/ Biotechnology Practice, Frost & Sullivan.
Frost & Sullivan Healthcare Practice has a team of more than 90 experienced analysts in Asia Pacific dedicated to research in the pharmaceuticals, medical devices, biotechnology, healthcare IT markets as well as emerging technology trends in the region.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, partners with clients to accelerate their growth. The company's TEAM Research, Growth Consulting and Growth Team Membership empower clients to create a growth-focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents. For more information about Frost & Sullivan's Growth Partnerships, visit http://www.frost.com.
Frost & Sullivan Corporate Communications Healthcare,
Asia Pacific Jasminder KaurDid: +65 6890 0937 Mobile: +65 9062 7051
jkaur@frost.com or Corporate Communications Healthcare,
Asia Pacific Shereen GillDid: +603 6204 5909 Mobile: +6017 617 8300
shereen.gill@frost.com or Australia officeSuite 1, Level 9189
Kent StreetSydney, NSW AustraliaTel: +61 (0)2 8247 9800 Fax:
+61 (0)2 9252 8066
No comments:
Post a Comment